ERBB2 and breast carcinoma: Her2 positivity is a negative prognostic factor for breast cancer patients (16), and trastuzumab, the first approved anti-Her2 monoclonal antibody, is the most commonly used standard of care regimen for Her2-positive breast cancer patients worldwide.